Literature DB >> 18582900

Decreased prefrontal, anterior cingulate, insula, and ventral striatal metabolism in medication-free depressed outpatients with bipolar disorder.

John O Brooks1, Po W Wang, Julie C Bonner, Allyson C Rosen, Jennifer C Hoblyn, Shelley J Hill, Terence A Ketter.   

Abstract

This study explored whether cerebral metabolic changes seen in treatment resistant and rapid cycling bipolar depression inpatients are also found in an outpatient sample not specifically selected for treatment resistance or rapid cycling. We assessed 15 depressed outpatients with bipolar disorder (six type I and nine type II) who were medication-free for at least 2 weeks and were not predominantly rapid cycling. The average 28-item Hamilton Depression Scale (HAM-D) total score was 33.9. The healthy control group comprised 19 age-matched subjects. All participants received a resting quantitative 18F-fluoro-deoxyglucose positron emission tomography scan. Data analyses were performed with Statistical Parametric Mapping (SPM5). Analyses revealed that depressed patients exhibited similar global metabolism, but decreased absolute regional metabolism in the left much more than right dorsolateral prefrontal cortex, bilateral (left greater than right) insula, bilateral subgenual prefrontal cortex, anterior cingulate, medial prefrontal cortex, ventral striatum, and right precuneus. No region exhibited absolute hypermetabolism. Moreover, HAM-D scores inversely correlated with absolute global metabolism and regional metabolism in the bilateral medial prefrontal gyrus, postcentral gyrus, and middle temporal gyrus. Analysis of relative cerebral metabolism yielded a similar, but less robust pattern of findings. Our findings confirm prefrontal and anterior paralimbic metabolic decreases in cerebral metabolism outside of inpatients specifically selected for treatment resistant and rapid cycling bipolar disorder. Prefrontal metabolic rates were inversely related to severity of depression. There was no evidence of regional hypermetabolism, perhaps because this phenomenon is less robust or more variable than prefrontal hypometabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582900      PMCID: PMC3265392          DOI: 10.1016/j.jpsychires.2008.04.015

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  22 in total

1.  Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism.

Authors:  Wayne C Drevets; Wendy Bogers; Marcus E Raichle
Journal:  Eur Neuropsychopharmacol       Date:  2002-12       Impact factor: 4.600

2.  The different versions of the Hamilton Depression Rating Scale.

Authors:  F G Zitman; M F Mennen; E Griez; C Hooijer
Journal:  Psychopharmacol Ser       Date:  1990

3.  Reduction of prefrontal cortex glucose metabolism common to three types of depression.

Authors:  L R Baxter; J M Schwartz; M E Phelps; J C Mazziotta; B H Guze; C E Selin; R H Gerner; R M Sumida
Journal:  Arch Gen Psychiatry       Date:  1989-03

4.  Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder.

Authors:  T A Ketter; T A Kimbrell; M S George; R T Dunn; A M Speer; B E Benson; M W Willis; A Danielson; M A Frye; P Herscovitch; R M Post
Journal:  Biol Psychiatry       Date:  2001-01-15       Impact factor: 13.382

5.  A rating scale for mania: reliability, validity and sensitivity.

Authors:  R C Young; J T Biggs; V E Ziegler; D A Meyer
Journal:  Br J Psychiatry       Date:  1978-11       Impact factor: 9.319

6.  Evidence for common alterations in cerebral glucose metabolism in major affective disorders and schizophrenia.

Authors:  R M Cohen; W E Semple; M Gross; T E Nordahl; A C King; D Pickar; R M Post
Journal:  Neuropsychopharmacology       Date:  1989-12       Impact factor: 7.853

7.  Regional cerebral glucose utilization in patients with a range of severities of unipolar depression.

Authors:  Tim A Kimbrell; Terence A Ketter; Mark S George; John T Little; Brenda E Benson; Mark W Willis; Peter Herscovitch; Robert M Post
Journal:  Biol Psychiatry       Date:  2002-02-01       Impact factor: 13.382

8.  Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18.

Authors:  L R Baxter; M E Phelps; J C Mazziotta; J M Schwartz; R H Gerner; C E Selin; R M Sumida
Journal:  Arch Gen Psychiatry       Date:  1985-05

9.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls.

Authors:  L R Baxter; M E Phelps; J C Mazziotta; B H Guze; J M Schwartz; C E Selin
Journal:  Arch Gen Psychiatry       Date:  1987-03

10.  Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness.

Authors:  M S Buchsbaum; J Wu; L E DeLisi; H Holcomb; R Kessler; J Johnson; A C King; E Hazlett; K Langston; R M Post
Journal:  J Affect Disord       Date:  1986 Mar-Apr       Impact factor: 4.839

View more
  25 in total

1.  Effect of Bcl-2 rs956572 SNP on regional gray matter volumes and cognitive function in elderly males without dementia.

Authors:  Mu-En Liu; Chu-Chung Huang; Jen-Ping Hwang; Albert C Yang; Pei-Chi Tu; Heng-Liang Yeh; Chen-Jee Hong; Ying-Jay Liou; Jin-Fan Chen; Ching-Po Lin; Shih-Jen Tsai
Journal:  Age (Dordr)       Date:  2011-12-25

2.  A longitudinal functional connectivity analysis of the amygdala in bipolar I disorder across mood states.

Authors:  Michael A Cerullo; David E Fleck; James C Eliassen; Matt S Smith; Melissa P DelBello; Caleb M Adler; Stephen M Strakowski
Journal:  Bipolar Disord       Date:  2012-03       Impact factor: 6.744

3.  Preliminary evidence of within-subject changes in gray matter density associated with remission of bipolar depression.

Authors:  John O Brooks; Lara C Foland-Ross; Paul M Thompson; Lori L Altshuler
Journal:  Psychiatry Res       Date:  2011-05-10       Impact factor: 3.222

4.  Different neural pathways to negative affect in youth with pediatric bipolar disorder and severe mood dysregulation.

Authors:  Brendan A Rich; Frederick W Carver; Tom Holroyd; Heather R Rosen; Jennifer K Mendoza; Brian R Cornwell; Nathan A Fox; Daniel S Pine; Richard Coppola; Ellen Leibenluft
Journal:  J Psychiatr Res       Date:  2011-05-10       Impact factor: 4.791

Review 5.  The development and course of bipolar spectrum disorders: an integrated reward and circadian rhythm dysregulation model.

Authors:  Lauren B Alloy; Robin Nusslock; Elaine M Boland
Journal:  Annu Rev Clin Psychol       Date:  2015-01-12       Impact factor: 18.561

Review 6.  Molecular imaging in patients with mood disorders: a review of PET findings.

Authors:  Qiaozhen Chen; Weibo Liu; Huichun Li; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

7.  Spontaneous low-frequency fluctuations in the neural system for emotional perception in major psychiatric disorders: amplitude similarities and differences across frequency bands

Authors:  Miao Chang; Elliot K. Edmiston; Fay Y. Womer; Qian Zhou; Shengnan Wei; Xiaowei Jiang; Yifang Zhou; Yuting Ye; Haiyan Huang; Xi-Nian Zuo; Ke Xu; Yanqing Tang; Fei Wang
Journal:  J Psychiatry Neurosci       Date:  2019-03-01       Impact factor: 6.186

Review 8.  The immunology of bipolar disorder.

Authors:  Izabela Guimarães Barbosa; Rodrigo Machado-Vieira; Jair C Soares; Antonio L Teixeira
Journal:  Neuroimmunomodulation       Date:  2014-02-14       Impact factor: 2.492

Review 9.  Neurocognitive and neuroimaging predictors of clinical outcome in bipolar disorder.

Authors:  Carrie E Bearden; Michelle Woogen; David C Glahn
Journal:  Curr Psychiatry Rep       Date:  2010-12       Impact factor: 5.285

10.  Dorsolateral and dorsomedial prefrontal gray matter density changes associated with bipolar depression.

Authors:  John O Brooks; Julie C Bonner; Allyson C Rosen; Po W Wang; Jennifer C Hoblyn; Shelley J Hill; Terence A Ketter
Journal:  Psychiatry Res       Date:  2009-04-05       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.